An Angiogenic Switch in Breast Cancer Involves Estrogen and Soluble Vascular Endothelial Growth Factor Receptor 1

Michael Elkin, Adam Orgel, Hynda K. Kleinman

Estrogen is involved in breast tumorigenesis, but the precise mechanisms for its oncogenic and angiogenic actions are poorly understood. Angiogenesis is regulated, in part, by these critical components: vascular endothelial growth factor (VEGF) and its two receptors (VEGFR-1 and VEGFR-2). VEGFR-2 is a positive angiogenic signal transducer, whereas VEGFR-1, especially its soluble form (soluble VEGFR-1), is a negative regulator of VEGF availability. We found that breast epithelial cells express soluble VEGFR-1 and hypothesized that because estrogen can regulate expression of members of the VEGF family, it might stimulate angiogenesis in breast cancer by decreasing expression of soluble VEGFR-1. Soluble VEGFR-1 expression decreased in estrogen receptor (ER)–positive but not in ER-negative breast cancer cell lines treated with estrogen. Pretreatment of the cells with the ER antagonist ICI 182,780 blocked the effect. The estrogen-mediated decrease in soluble VEGFR-1 expression was accompanied by a statistically significant increase in angiogenesis in vivo. Our data suggest that inhibition of soluble VEGFR-1 expression represents a novel mechanism—an estrogen-driven angiogenic switch—possibly responsible for breast carcinoma progression. [J Natl Cancer Inst 2004;96:875–8]
length membrane receptor (≈200 kd) and a soluble receptor (≈110 kd), which are generated by alternative splicing of the VEGFR-1 pre-mRNA and contain the extracellular ligand-binding domains but lack the signaling tyrosine kinase domains (4). VEGFR-1 has more than a 40-fold higher affinity than VEGFR-2 for VEGF (4,6). It is believed that VEGFR-1 functions as an inert decoy by binding endogenous VEGF, thereby negatively regulating the availability of VEGF and the activation of angiogenesis through VEGFR-2. Such a decoy function is attributable mainly to soluble VEGFR-1 (4). Several studies have used soluble VEGFR-1 as a VEGF-blocking reagent (i.e., negative regulator of angiogenesis) and as an inhibitor of tumor growth (6–9).

Although expression of VEGFR-1 was previously believed to be restricted to the vascular endothelium, VEGFR-1 has been detected in several types of non-endothelial cells—breast cancer cells in particular (10,11). We used western blot analysis (Fig. 1) and immunofluorescent staining (data not shown) to determine levels of VEGFR-1 protein in normal breast cell lines (Hs578Bst; obtained from American Type Culture Collection [ATCC], Manassas, VA) and in two breast carcinoma cell lines (MCF-7, obtained from ATCC, and MDA-MB-231, obtained from Dr. P. Steeg, National Cancer Institute, Bethesda, MD) and compared the levels to those in human umbilical vein endothelial cells (HUVECs). Whereas vascular endothelial cells expressed a substantial fraction of the total VEGFR-1 protein as the full-length, membrane-spanning form of the receptor, normal and breast cancer cell lines expressed soluble VEGFR-1 almost exclusively (Fig. 1).

Because estrogen can modulate transcription of genes encoding other members of the VEGF signaling pathway (12,13), we next tested whether estrogen affects expression of VEGFR-1. We treated estrogen-responsive MCF-7 breast carcinoma cells with physiologic concentrations of estrogen for 8 hours and used semiquantitative reverse transcription–polymerase chain reaction (RT-PCR) and primers especially designed to amplify sequences specific for either full-length or soluble VEGFR-1 (described in (9)). We found that, compared with VEGFR-1 levels in control-treated MCF-7 cells, levels of soluble VEGFR-1 mRNA were markedly decreased in estrogen-treated MCF-7 cells, whereas levels of full-length VEGFR-1 mRNA were unchanged (Fig. 2, A). We confirmed the estrogen receptor (ER) status of MCF-7, T47D, and MDA-MB-231 cell lines used in these experiments in proliferation assays (data not shown) and then tested whether the observed effect on soluble VEGFR-1 was mediated through the ER pathway by incubating the breast cancer cells with the ER antagonist ICI 182,780 (14) before treating them with estrogen. Estrogen-mediated inhibition of soluble VEGFR-1 mRNA expression was abolished in a dose-dependent manner in cells treated with ICI 182,780 (Fig. 2, B). Estrogen-induced decreases in soluble VEGFR-1 protein levels were also blocked in ER-positive MCF-7 and T47D cells treated with ICI 182,780 (Fig. 2, C). By contrast, estrogen with or without ICI 182,780 had no effect on soluble VEGFR-1 expression in ER-negative MDA-MB-231 breast carcinoma cells (Fig. 2, C). Estrogen-like inhibition of soluble VEGFR-1 mRNA and protein levels was observed in MCF-7 cells treated with the nonsteroidal partial estrogen antagonist tamoxifen (Fig. 2, D). These results demonstrate the involvement of the classical ER pathway in estrogen-mediated soluble VEGFR-1 expression.

We next used the Matrigel plug assay (15) to investigate the estrogen-mediated inhibition of VEGFR-1 expression in vivo and its possible correlation with breast carcinoma–induced angiogenesis. To regulate the in vivo estrogen levels, we removed the ovaries from 6-week-old female BALB/c nude mice and implanted placebo or slow-release estrogen pellets. MCF-7 cells (1 × 10⁶) were mixed with 0.2 mL of Matrigel and injected subcutaneously into the back of each mouse. After 6 days, the Matrigel–cell plugs were removed and analyzed for VEGFR-1 protein expression by immunohistochemistry. Levels of VEGFR-1 protein were lower in Matrigel-embedded MCF-7 cells from mice implanted with estrogen pellets (Fig. 2, E, right panel) than in Matrigel-embedded MCF-7 cells from mice with placebo pellets (Fig. 2, E, left panel). This decrease in VEGFR-1 expression was associated with a pronounced increase in the angiogenic response, reflected by a statistically significant increase in vascular density (mean = 2.08 vessels per microscopic field) measured in the Matrigel plugs from estrogen-treated mice compared with vascular density measured in the Matrigel plugs from placebo-treated mice (0.94 vessels per microscopic field; mean difference = 1.14 , 95% confidence interval [CI] = 0.44 to 1.82; P = .002 , Welch t test). These data demonstrate that estrogen decreases VEGFR-1 expression in vivo. Consequently, because VEGFR-1 negatively regulates angiogenesis (6–9), this decrease in VEGFR-1 expression may be associated with increased neovascularization within a tumor.

Our results suggest that the inhibition of VEGFR-1 expression could present a novel mechanism by which estrogen exerts pro-angiogenic effects and thus promotes breast cancer development or progression. It is conceivable that normal breast tissue cells constitutively express soluble VEGFR-1 at levels sufficient to absorb endogenous VEGF, thus prevent-
the induction of inappropriate angiogenesis and cell growth. In agreement with this proposed mechanism, a recent study (16) has shown the presence of endogenous soluble VEGFR-1 at concentrations as high as 440 pg/mL in biologic fluids from normal human subjects. In normal breast tissue, estrogen is unlikely to inhibit VEGFR-1 expression because only a minority of normal breast epithelial cells (7%–17%) express detectable ER levels (17,18). However, in primary breast tumors, the majority of proliferating breast cancer cells are ER-positive (18,19), and estrogen, by reducing the levels of VEGFR-1, may increase the levels of VEGF available to activate angiogenesis. Thus, estrogen triggers an angiogenic switch and further promotes tumor progression. This proposed mechanism is supported by the fact that patients whose tumors had soluble VEGFR-1 levels at least 10-fold higher than their tumor VEGF levels had...
The classical mechanism of estrogen action involves formation of an estrogen–ER complex that binds to the estrogen response element (ERE) in target promoters and modulates (by increasing or decreasing) gene transcription (21). However, analysis of the VEGFR-1 gene 1.5-kilobase regulatory sequence (22) using MatInspector software (23) revealed a lack of formal EREs in the promoter region, suggesting that the effect of estrogen on soluble VEGFR-1 expression is mediated by interactions between the estrogen–ER complex and additional transcription modulators. Such an ER-mediated but ERE-independent pathway has been reported for a number of estrogen-regulated genes (21). Some transcription factors regulating VEGFR-1 expression (i.e., Egr-1, Ets) (24,25) have been previously shown to mediate the cellular effects of estrogen (26,27). Because steroid hormones simultaneously control gene transcription and alternative splicing (28), the observed action of estrogen on VEGFR-1 expression may reflect effects on both transcriptional and post-transcriptional (i.e., alternative RNA processing) regulatory events that are involved in the generation of soluble VEGFR-1.

Regulation of soluble VEGFR-1 by estrogen may represent one of the molecular pathways responsible for the angiogenic switch during breast tumorigenesis. Detailed understanding of the role of estrogen and antiestrogens (i.e., tamoxifen) used in clinical settings to control VEGFR-1 expression may help in the design of new strategies for preventing resistance to endocrine therapy and may also help clarify the emerging role of estrogen in controlling vascularization.

REFERENCES


NOTES

Present address: M. Elkin, Department of Oncology, Hadassah University Hospital, Jerusalem, Israel.

Supported in part by the German-Israeli Foundation for Scientific Research & Development (GIF). Manuscript received November 6, 2003; revised March 17, 2004; accepted March 26, 2004.